Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.
Mizuki KobayashiShintaro NaritaYoshiyuki MatsuiSouhei KandaYu HidakaHiroyasu AbeToyonori TsuzukiKatsuhiro ItoTakahiro KojimaMinoru KatoShingo HatakeyamaYuto MatsushitaSei NaitoMasanobu ShigaMakito MiyakeYusuke MuroShotaro NakanishiYoichiro KatoTadamasa ShibuyaTetsutaro HayashiHiroaki YasumotoTakashi YoshidaMotohide UemuraRikiya TaokaManabu KamiyamaSatoshi MoritaTomonori HabuchiOsamu OgawaHiroyuki NishiyamaHiroshi KitamuraTakashi Kobayashinull nullPublished in: BJU international (2021)
The presence of variant histology did not seem to affect BOR or OS after pembrolizumab administration in patients with chemo-resistant UC. The patients with sarcomatoid VUC achieved favourable responses and survival rates compared to PUC.
Keyphrases
- advanced non small cell lung cancer
- photodynamic therapy
- copy number
- squamous cell carcinoma
- type diabetes
- gene expression
- cancer therapy
- locally advanced
- insulin resistance
- adipose tissue
- combination therapy
- metabolic syndrome
- dna methylation
- epidermal growth factor receptor
- skeletal muscle
- rectal cancer
- tyrosine kinase